Common use of NOTIFICATIONS AND SUBMISSION OF REPORTS Clause in Contracts

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx Xxxxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 AstraZeneca: Xxxxx X. Xxxxxxx U.S. Compliance Officer AstraZeneca Pharmaceuticals LP 0000 Xxxxxxx Xxxx XX Xxx 00000 Xxxxxxxxxx, XX 00000-0000 Telephone: 000.000.0000 Facsimile: 302.885.9093 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK AstraZeneca may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Ensign Group: Xxxxxxx X. Xxxxxx Chief Compliance Officer The Ensign Group, Inc. 27101 Puerta Real, Xxxxx 000 Xxxxxxx Xxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 888.519.8334 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Ensign Group may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 All Smiles: Xxxxxxx X. X. Xxxxxx, Esq. Chief Compliance Officer All Smiles Dental Centers 0000 XXX Xxxxxxx, Xxxxx 000 Xxxxxx, Xxxxx 00000 Office: 000.000.0000 Fax: 000.000.0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK All Smiles may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Rotech: Xxxxx Xxxxxxx Chief Compliance Officer Rotech Healthcare Inc. 0000 Xxxxxxxxxx Xxxxx Xxxxx 000 Xxxxxxx, XX 00000 Phone: 000-000-0000 Fax: 000-000-0000 Rotech Healthcare Inc. Corporate Integrity Agreement Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Rotech may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKBIPI: Xxxxxxx X. Xxxx Vice President & Xxxxxxxxxx Xxxxxxxxx Chief Ethics and Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxx Xxxx Ridgefield, XX 00000 CT 00000-0000 Telephone: 000.000.0000 Facsimile: 215.751.7547 203.791.6260 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK BIPI may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Shire: Xxxxxxxx X. Xxxx Senior Vice President and Chief Compliance and Risk Officer Shire Pharmaceuticals LLC 000 Xxxxxxxxxxxx Xxxx. Xxxxx, XX 00000 Telephone: (000) 000-0000 Facsimile: (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, Shire North American Group, Inc. Corporate Integrity Agreement internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Shire may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA IA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXX Xxxxxxxxxx, XX 00000 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 Chatterjee Compliance Contact: Xxxxxxxxxx Xxxxxxxxxx, M.D. 0000 Xxxx 0xx Xxxxxx Suite B London, KY 40741 Telephone: 000-000-0000 Facsimile: 000-000-0000 Unless otherwise specified, all notifications and reports required by this CIA may IA shall be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Xxxxxxxxxx may be required to provide OIG with an electronic copy of each notification or report required by this CIA IA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKShire: Xxxxxxx Xxxxxxxx X. Xxxx Senior Vice President & and Chief Compliance and Risk Officer North America Shire Pharmaceuticals GlaxoSmithKline Three Franklin Plaza LLC 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxxxx Xxxx. Wayne, XX 00000 PA 19087 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, Shire North American Group, Inc. Corporate Integrity Agreement internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Shire may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Boston Scientific: Xxxx Xxxxxxxx Xxxxx Chief Compliance Officer Xxx Xxxxxx Xxxxx Xxxxx Xxxxx, XX 00000 Telephone No: 000-000-0000 Facsimile No: 000-000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Boston Scientific may be required to provide OIG with an electronic copy of each Boston Scientific Corp. Corporate Integrity Agreement notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 Allergan: Chief Compliance Officer Allergan, Inc. 0000 Xxxxxx Xxxxx X.X. Xxx 00000 Xxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 714.246.4971 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Allergan may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKPHC: Xxxxxxx X. Xxxx Vice President & Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza Pacific Health Corporation 0000 Xxxxxxxx Xxxxxxxxx, Xxxxx 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxx Xxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 213.355.1540 Email: xxxxx@xxxxxxxxxxxxxxxxx.xxx Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK PHC may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Cxxxx Building, Room 5527 000 300 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 200.000.0000 Facsimile: 215.751.7547 202.205.0604 Baxano Surgical: Sxxxxxxxx Xxxxx Vice President of Regulatory, Quality and Compliance and Chief Compliance Officer 100 Xxxxxxx Xxxxx Xxxxxxx, XX 00000 Telephone: 900-000-0000 Facsimile: 900-000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Baxano Surgical may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General General‌ U.S. Department of Health and Human Services Endo Pharmaceuticals Inc. Corporate Integrity Agreement Xxxxx Building, Room 5527 0000 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKEndo: Xxx Xxxxxxx X. Xxxx Executive Vice President & and Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxEndo Health Solutions Inc. 0000 Xxxxxxx Xxxxx Malvern, XX 00000 PA 19335 Telephone: 000.000.0000 Facsimile: 215.751.7547 484.713.5204 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK EPI may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSKVanguard: Xxxxxxx X. Xxxx Vice President & Xxxxxx Xxx Xxxxxx, Chief Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza Vanguard Healthcare Services, LLC 0 Xxxxxxxx Xxxxx, Xxxxx 000 X. 00xx Xxxxxx XxxxxxxxxxxxBrentwood, XX 00000 TN 37027 Telephone: 000.000.0000 Facsimile: 215.751.7547 615.324.4945 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Vanguard may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 202.205.0604 GSK(000) 000-0000 ION: Xxxxxxx Xxxxx XxXxxxxx, Compliance Director Integrated Oncology Network 0000 X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza Xxxxx Xxxxxxx, Xxxxx 000 X. 00xx Xxxxxx Xxxxxxxxxxxxxxx Xxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may shall be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK ION may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf)CIA, either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 215.751.7547 202.205.0604 The DIG Entities: Xxxx Xxxxxxx Executive Vice President and Compliance Officer Diagnostic Imaging Group, LLC 000 Xxxxx Xxxxxxxx Xxxxxxxxxx, XX 00000 Telephone: 000.000.0000 Facsimile: 516.977.1451 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK the DIG Entities may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, to a paper copy.

NOTIFICATIONS AND SUBMISSION OF REPORTS. Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this CIA shall be submitted to the following entities: OIG: Administrative and Civil Remedies Branch Office of Counsel to the Inspector General Office of Inspector General U.S. Department of Health and Human Services Xxxxx Building, Room 5527 000 Xxxxxxxxxxxx Xxxxxx, X.X. Washington, DC 20201 Telephone: 000.000.0000 Facsimile: 202.205.0604 GSK: Xxxxxxx X. Xxxx Vice President & Compliance Officer North America Pharmaceuticals GlaxoSmithKline Three Franklin Plaza 000 X. 00xx Xxxxxx XxxxxxxxxxxxXxxxxxxxxx, XX 00000 Telephone: 000.000.0000 (000) 000-0000 Facsimile: 215.751.7547 (000) 000-0000 CEPHALON: Executive Vice President, Chief Compliance Officer Cephalon, Inc. 00 Xxxxxx Xxxx Frazer, PA 19355 Phone: (000) 000-0000 Facsimile: (000) 000-0000 Unless otherwise specified, all notifications and reports required by this CIA may be made by certified mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. For purposes of this requirement, internal facsimile confirmation sheets do not constitute proof of receipt. Upon request by OIG, GSK Cephalon may be required to provide OIG with an electronic copy of each notification or report required by this CIA in searchable portable document format (pdf), either instead of or in addition to, a paper copy.